Sino Biopharmaceutical Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Sino Biopharmaceutical (HKG:1177) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥28.9b (up 10% from FY 2023).
• Net income: CN¥1.92b (up 3.9% from FY 2023).
• Profit margin: 6.7% (down from 7.1% in FY 2023).
• EPS: CN¥0.10 (up from CN¥0.10 in FY 2023).

Our free stock report includes 1 warning sign investors should be aware of before investing in Sino Biopharmaceutical. Read for free now.

1177 Post-Clinical Trial Products

• Approved (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sino Biopharmaceutical EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 3.7%.

The primary driver behind last 12 months revenue was the Modernised Chinese Medicines and Chemical Medicines segment contributing a total revenue of CN¥28.5b (99% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥10.1b (47% of total expenses). Explore how 1177's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Sino Biopharmaceutical is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.